Cargando…

Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice

Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubrovsky, Alanna M., Nyman, Jeffrey S., Uppuganti, Sasidhar, Chmiel, Kenneth J., Kimmel, Donald B., Lane, Nancy E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990143/ https://www.ncbi.nlm.nih.gov/pubmed/33778319 http://dx.doi.org/10.1002/jbm4.10443

Ejemplares similares

Prevalence of glucocorticoid induced osteonecrosis in the mouse is not affected by treatments that maintain bone vascularity
por: Lane, Nancy E., et al.
Publicado: (2018)

Inhibition of vascular endothelial growth factor in young adult mice causes low bone blood flow and bone strength with no effect on bone mass in trabecular regions
por: Lane, N.E., et al.
Publicado: (2019)

Assessing matrix quality by Raman spectroscopy helps predict fracture toughness of human cortical bone
por: Unal, Mustafa, et al.
Publicado: (2019)

Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes
por: Nyman, Jeffry S., et al.
Publicado: (2017)

Manipulating the Amount and Structure of the Organic Matrix Affects the Water Compartments of Human Cortical Bone
por: Nyman, Jeffry S, et al.
Publicado: (2019)

Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1
por: de la Croix Ndong, Jean, et al.
Publicado: (2014)

Inhibition of TGF‐β Increases Bone Volume and Strength in a Mouse Model of Osteogenesis Imperfecta
por: Greene, Benjamin, et al.
Publicado: (2021)

Pharmacologic Inhibition of Myostatin With a Myostatin Antibody Improves the Skeletal Muscle and Bone Phenotype of Male Insulin‐Deficient Diabetic Mice
por: Bunn, R Clay, et al.
Publicado: (2023)

Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice
por: Brent, Mikkel Bo, et al.
Publicado: (2021)

Autologous chondrocyte grafting promotes bone formation in the posterolateral spine
por: Sielatycki, J. Alex, et al.
Publicado: (2018)

Bone mineral density and muscle mass in adults with developmental skeletal discrepancies
por: Sharifi, Reza, et al.
Publicado: (2022)

Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia
por: Chandler, H., et al.
Publicado: (2019)

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
por: Geusens, Piet, et al.
Publicado: (2022)

Callus γδ T cells and microbe-induced intestinal Th17 cells improve fracture healing in mice
por: Dar, Hamid Y., et al.
Publicado: (2023)

Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids
por: Sawamura, Masato, et al.
Publicado: (2017)

Supraphysiologic glucocorticoid administration increased biomechanical bone strength of rats' vertebral body
por: Najar, Azam, et al.
Publicado: (2015)

Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice
por: Krüger, Benjamin Thilo, et al.
Publicado: (2022)

Bisphosphonates for Prevention of Bone Loss in Glucocorticoid-Treated Young People
por: Reid, Ian R.
Publicado: (2019)

Differential Maintenance of Cortical and Cancellous Bone Strength Following Discontinuation of Bone-Active Agents
por: Shahnazari, Mohammad, et al.
Publicado: (2011)

Glucocorticoids: bad or safe for the bones?
por: Lems, Willem F
Publicado: (2015)

Glucocorticoids and Trabecular Bone Score
por: Sandru, Florica, et al.
Publicado: (2020)

Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice
por: Funck-Brentano, Thomas, et al.
Publicado: (2018)

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats
por: Suen, Pui Kit, et al.
Publicado: (2015)

FRI681 Osteoboost(Tm) Is Effective In Preserving Bone Strength And Density Of The Spine In Women With Low Bone Mass
por: Bilek, Laura D, et al.
Publicado: (2023)

PYY is a negative regulator of bone mass and strength
por: Leitch, Victoria D., et al.
Publicado: (2019)

Effects of the energy balance transition on bone mass and strength
por: Wallace, Ian J., et al.
Publicado: (2023)

Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass
por: Guan, Min, et al.
Publicado: (2012)

Treatments of osteoporosis increase bone material strength index in patients with low bone mass
por: Schoeb, M., et al.
Publicado: (2020)

The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy
por: Annexstad, E. J., et al.
Publicado: (2019)

Distinct Glucocorticoid Receptor Actions in Bone Homeostasis and Bone Diseases
por: Lee, Sooyeon, et al.
Publicado: (2022)

Inhibition of the Progesterone Nuclear Receptor during the Bone Linear Growth Phase Increases Peak Bone Mass in Female Mice
por: Yao, Wei, et al.
Publicado: (2010)

Editorial: Glucocorticoid and bone: Friend or foe
por: Baschant, Ulrike, et al.
Publicado: (2022)

Comparison of the Effect of Vitamin K(2) and Risedronate on Trabecular Bone in Glucocorticoid-Treated Rats: A Bone Histomorphometry Study
por: Iwamoto, Jun, et al.
Publicado: (2009)

Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis
por: Ueland, Thor, et al.
Publicado: (2019)

Extracellular Vesicles from Child Gut Microbiota Enter into Bone to Preserve Bone Mass and Strength
por: Liu, Jiang‐Hua, et al.
Publicado: (2021)

Bone Mass and Strength and Fall-Related Fractures in Older Age
por: Uusi-Rasi, Kirsti, et al.
Publicado: (2019)

High dose dietary vitamin D(3) increases bone mass and strength in mice
por: Williamson, Liam, et al.
Publicado: (2017)

Strain-specific differences in the development of bone loss and incidence of osteonecrosis following glucocorticoid treatment in two different mouse strains
por: Shidara, Kie, et al.
Publicado: (2018)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe
por: Martin, Claire S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_it8tch3j9b58ao9qlj8v0744e3